NCT01218659 - Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 8, 2011

Primary Completion Date

May 27, 2014

Study Completion Date

May 28, 2015

Conditions

Fabry Disease

Interventions

DRUG

migalastat hydrochloride

150-mg capsule administered orally QOD

BIOLOGICAL

agalsidase

Agalsidase via intravenous infusion as prescribed by the participant's treating physician and in accordance with the approved prescribing information

Trial Locations (25)

1090

Vienna

2100

Copenhagen

2650

Edegem

6000

Perth

15224

Pittsburgh

22030

Fairfax

30033

Decatur

49525

Grand Rapids

50129

Florence

53226

Milwaukee

59037

Lille

80045

Aurora

90048

Los Angeles

92380

Garches

97239

Portland

03050

Parkville

14048-900

São Paulo

951-8520

Niigata

545-8586

Osaka

565-0871

Osaka

105-8471

Tokyo

CB2 0QQ

Cambridge

NW3 2QG

London

WC1N 3BG

London

M6 8HD

Salford